IMPEDIMED LIMITED (IPD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IPD

IPD - IMPEDIMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.74
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.034

08 Jan
2026

0.000

OPEN

$0.03

0.000

HIGH

$0.04

2,510,569

LOW

$0.03

TARGET
$0.107 213.7% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
IPD: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 1.2 - 0.8 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-1.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx12.7 M
Book Value Per Share xxxxxxxxxxxxxxx1.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-15.2 M
Net Profit Margin xxxxxxxxxxxxxxx-182.62 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-75.89 %
Return on Invested Capital xxxxxxxxxxxxxxx-60.93 %
Return on Assets xxxxxxxxxxxxxxx-52.43 %
Return on Equity xxxxxxxxxxxxxxx-75.89 %
Return on Total Capital xxxxxxxxxxxxxxx-62.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-15.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx14 M
Total Debt xxxxxxxxxxxxxxx14 M
Goodwill - Gross xxxxxxxxxxxxxxx3 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx22 M
Price To Book Value xxxxxxxxxxxxxxx3.46

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx1.0 M
Capex % of Sales xxxxxxxxxxxxxxx7.77 %
Cost of Goods Sold xxxxxxxxxxxxxxx28 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx9 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxxxxx xx xxxxxxxx xxxx xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

05/11/2025

1

Speculative Buy

$0.13

282.35%

Morgans notes ImpediMed’s first-quarter cash flow was below expectations due to hospital approval delays and foreign exchange impacts.

Installed base growth of 26 units in the US fell short of the 40-unit forecast, though growth is expected to recover in coming quarters.

Revenue rose 9% quarter-on-quarter despite a -9% forex headwind, with annual recurring revenue up 3% on the June quarter and 24% year-on-year.

Morgans has reduced its FY26 Sozo unit forecast to 196 from 210, increasing the estimated net loss to -$14.7m from -$13.5m.

The target price is trimmed to 13c from 14c, and the Speculative Buy rating is retained.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.70 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.30 cents.

Ord Minnett

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

10/10/2025

1

Speculative Buy

$0.07

105.88%

Canaccord Genuity retains a Speculative Buy rating and $0.07 target on ImpediMed while lowering forecasts by -30% to -40% for total contract win rates and revenue, respectively.

The broker assesses functional US reimbursement coverage for SOZO is now achieved at around 86% of covered lives, with Texas providing critical mass.

Sales deployment is the current constraint, with only 13 field roles and two business development staff supporting roll-out.

FY26 is expected to deliver steady development at fixed cost circa -$30m opex, delaying profitability and implying a $25m equity raise is expected by the analyst in FY27

Canaccord Genuity believes the reimbursement “hard parts” are complete and the opportunity now hinges on scaling the sales force .

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.00 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
Access Extra Coverage Research History >

IPD STOCK CHART

FNArena News on IPD

1
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
2
Australian Broker Call *Extra* Edition – Oct 16, 2025

Oct 16 2025 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Oct 07, 2025

Oct 07 2025 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Sep 08, 2025

Sep 08 2025 - Daily Market Reports
5
FNArena Corporate Results Monitor – 29-08-2025

Aug 29 2025 - Australia

Latest Medical Equipment & Devices News

1
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
2
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
3
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
4
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
5
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
6
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
7
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
8
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
9
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
10
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia